P169Eligibility for PCSK9 inhibitors according to ESC/EAS and ACC recommendations after acute coronary syndromes

K.C. Koskinas, B. Gencer, L. Raeber, A. Karagiannis, D. Nanchen, D. Carballo, S. Carballo, R. Klingenberg, D. Heg, C. Matter, T.F. Luscher, N. Rodondi (+2 others)
2017 European Heart Journal  
Lipid-lowering therapy: old faces and new issues 29 ing taken by 25.7% of patients with an indication; 47.3% of patients with MI or coronary revascularization were taking a statin compared with 40.4%, 33.8% and 18.9% with diabetes, LDL-C ≥190mg/dL and 10-year CVD risk ≥7.5% respectively (Table 1 ). In multivariable analysis and compared with patients with history of MI or coronary revascularization, those with diabetes, LDL-C ≥190 mg/dL, and 10-year CVD risk ≥7.5% were less likely to be taking
more » ... statin (prevalence ratio [95% confidence interval] 0.68 [0.58-0.79], 0.71 [0.50-1.01], and 0.39 [0.34-0.46], respectively). Among patients who had ever taken a statin, 27.7% had discontinued treatment before 2013: 23.6% with history of MI or coronary revascularization, 27.7% with diabetes, 30.9% with LDL-C ≥190 mg/dL and 27.9% of those with 10-year CVD risk ≥7.5%. Background: Low density lipoprotein cholesterol (LDL-C) lowering with high dose statin therapy is a cornerstone in secondary prevention post-myocardial infarction (MI) with a treatment goal of <1.8 mmol/L. LDL-C is an established risk factor for atherosclerotic cardiovascular disease (ASCVD) in the general population, but the significance of LDL-C for ASCVD risk in post-MI patients remains unclear and the current LDL-C goal for treatment is based on circumstantial evidence.
doi:10.1093/eurheartj/ehx501.p169 fatcat:4jxe6di7c5e6rhcjcnmup5kpuq